Research Paper Title
Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction
Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy.
Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps “accelerated biological ageing,” suggesting widespread physical concomitants.
Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials.
To elucidate the potential involvement of metabolism, inflammation, and mitochondrial function in PTSD, the researchers integrate findings and mechanistic models from the DOD-sponsored “Systems Biology of PTSD Study” with previous data on these topics.
Data implicate inter-linked dysregulations in metabolism, inflammation, mitochondrial function, and perhaps the gut microbiome in PTSD.
Several inadequately tested targets of pharmacological intervention are proposed, including insulin sensitisers, lipid regulators, anti-inflammatories, and mitochondrial biogenesis modulators.
Systemic pathologies that are intricately involved in brain functioning and behaviour may not only contribute to somatic comorbidities in PTSD, but may represent novel targets for treating core psychiatric symptoms.
Bersani, F.S., Mellon, S.H., Lindqvist, D., Kang, J.I., Rampersaud, R., Somvanshi, P.R., Doyle, F.J., Hammamieh, R., Jett, M., Yehuda, R., Marmar, C.R. & Wolkowitz, O.M. (2020) Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction